{"groups":[{"description":"Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.\n\nGlutamine: Administered orally twice daily for 21 days","id":"FG000","title":"Arm I: Glutamine"},{"description":"Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.\n\nPlacebo: Administered orally twice daily for 21 days","id":"FG001","title":"Arm II: Placebo"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Fifty-six patients were enrolled and 49 were evaluable, with the reasons for removal from study after randomization due to: change in clinical status (N=3), family withdrew (N=2), family relocation (N=1) and other (N=1). 49 patients were randomized to the glutamine or placebo arm.","recruitmentDetails":"All subjects were consented according to Institutional Review Board approved guidelines during out routine outpatient or inpatient stay. The period of recruitment was from January 2007 to July 2011."}